← Back to Search

Other

LY3532226 for Obesity

Phase 1

Recruiting

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body mass index (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²)

Be older than 18 years old

Must not have

Known clinically significant gastric emptying abnormality, gastric bypass surgery, or restrictive bariatric surgery

Intend to use any weight-loss medications during study participation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose on day 1 through week 20

Summary

"This trial aims to test the safety of a drug called LY3532226 in obese individuals. Blood tests will be done to see how the drug enters and leaves the body after weekly or monthly doses.

Who is the study for?

This trial is for individuals with obesity. Specific details about who can join are not provided, but typically participants must meet certain health criteria and be willing to follow the study procedures.

What is being tested?

The study is testing LY3532226, a new potential treatment for obesity. Participants will receive either this drug or a placebo through weekly or monthly doses to evaluate its safety and how it's processed by the body.

What are the potential side effects?

Since LY3532226 is under investigation, exact side effects aren't listed here. Generally, clinical trials monitor for any adverse reactions ranging from mild (like headaches) to severe (affecting organ function).

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My weight is under 330 lbs and my BMI is between 30 and 40.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a known issue with how my stomach empties or have had certain types of weight loss surgery.

Select...

I plan to use weight-loss medications while in the study.

Select...

I haven't taken any weight loss drugs in the last 3 months.

Select...

My obesity is caused by a hormonal disorder or a specific genetic condition.

Select...

I have not been diagnosed with a major psychiatric disorder in the past 2 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose on day 1 through week 20

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose on day 1 through week 20

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 through week 20 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Secondary study objectives

Part A: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3532226

Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3532226

Part B: PK: AUC of LY3532226

+1 more